<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2394">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04386551</url>
  </required_header>
  <id_info>
    <org_study_id>PI2020_843_0045</org_study_id>
    <nct_id>NCT04386551</nct_id>
  </id_info>
  <brief_title>Detection of COVID-19 in Saliva Collection</brief_title>
  <acronym>SALICOV</acronym>
  <official_title>Evaluation of the Performance of a Saliva Sample Versus a Nasopharyngeal Sample in the Diagnosis of COVID-19 by RT-PCR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since December 2019, the world has faced a pandemic of COVID-19, an infectious disease caused
      by SARS-CoV-2, a virus that emerged in China. The reference diagnosis is based on the search
      for the SARS-COV-2 genome in the nasopharyngeal sample.

      Carrying out this sample requires the competence of a healthcare professional and presents
      some inconveniences for the tested patient. Because saliva collection is simple,
      non-invasive, painless and inexpensive, and can be performed by poorly trained personnel, it
      could be an alternative to the reference nasopharyngeal sample. SARS-CoV2 detection in human
      saliva could be a potential diagnosis of COVID infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of SARS-CoV-2 RNA in the saliva sample</measure>
    <time_frame>day 1</time_frame>
    <description>Detection of SARS-CoV-2 RNA in the saliva sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concordance between the Saliva sample and the nasonasopharyngeal sample SARS-CoV-2 RT-PCR results</measure>
    <time_frame>day 1</time_frame>
    <description>Concordance between the Saliva sample and the nasonasopharyngeal sample SARS-CoV-2 RT-PCR results</description>
  </primary_outcome>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Sars-CoV2</condition>
  <condition>RT-PCR</condition>
  <condition>Saliva Collection</condition>
  <condition>Nasopharyngeal Sample</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      nasopharyngeal sample and saliva sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult ambulatory patients screened for SARS Cov 19 at the CHU Amiens COViD clinic will be
        included in the study. A double sample will be taken from the saliva and the nasopharynx in
        parallel using the same sample kit. This double sampling has no direct impact on
        conventional patient management.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient hospitalized at the Amiens CHU in a COVID-19 unit

          -  patient seen as outpatient in the area of infectious pathologies for COVID-19
             infection

        Exclusion Criteria:

          -  Patients under 18

          -  patients under guardianship or curators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sandrine Castelain, Pr</last_name>
    <phone>(33)3 22 08 70 61</phone>
    <email>castelain.sandrine@chu-amiens.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Luc Schmit, Pr</last_name>
    <email>Schmit.Jean-Luc@chu-amiens.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine Castelain, Pr</last_name>
      <phone>(33) 3 22 08 70 61</phone>
      <email>castelain.sandrine@chu-amiens.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jean-Luc Schmit, Pr</last_name>
      <email>Schmit.Jean-Luc@chu-amiens.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Philippe Lanoix, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Fran√ßois, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Etienne Brochot, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves Edouard Herpe, Ing</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>September 17, 2020</last_update_submitted>
  <last_update_submitted_qc>September 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sars-CoV2</keyword>
  <keyword>RT-PCR</keyword>
  <keyword>Saliva collection</keyword>
  <keyword>nasopharyngeal sample</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

